SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0007 0920 OR L773:1532 1827 "

Sökning: L773:0007 0920 OR L773:1532 1827

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
41.
  • Dabrosin, Charlotta, 1961-, et al. (författare)
  • Oestradiol enhances tumour regression induced by B7-I/IL-2 adenoviral gene transfer in a murine model of breast cancer
  • 2003
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 89:2, s. 385-390
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>The majority of breast cancers are oestrogen dependent and although current treatment strategies have improved, approximately 50% of the patients will develop metastasis. New treatments that result in long-term systemic immunity are therefore being developed. We have previously shown that adenoviral gene transfer of B7-I/IL-2 to murine breast cancer induces a high rate of complete turnout regression and systemic immunity. Since oestrogens not only affect breast cancer but also have been shown to modulate immune function and secretion of immune-regulatory cytokines, we explored whether administration of oestradiol altered the immune response induced by an adenoviral vector expressing B7-I/IL-2. An oestrogen-dependent murine breast cancer tumour was used in ovariectomised mice, supplemented either oestradiol or placebo. We report the somewhat unexpected finding that intratumoral injection of adenovirus expressing B7-I/IL-2 induces complete turnout regression in 76% of oestradiol-supplemented mice, while only 18% of the tumours regressed in the oestrogen-depleted group. Cured mice in both groups exhibited a similar CTL response against the tumour antigen. However, intratumoral IFN-? levels, 2 days after B7-I/IL-2 injection, were significantly higher in mice treated with oestradiol compared to placebo. This may be one mechanism explaining the higher response rate of tumours in oestradiol-replenished mice.</p>
  •  
42.
  • Dahlman, I, et al. (författare)
  • Adipose tissue pathways involved in weight loss of cancer cachexia
  • 2010
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 102:10, s. 1541-8
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>BACKGROUND: The regulatory gene pathways that accompany loss of adipose tissue in cancer cachexia are unknown and were explored using pangenomic transcriptome profiling. METHODS: Global gene expression profiles of abdominal subcutaneous adipose tissue were studied in gastrointestinal cancer patients with (n=13) or without (n=14) cachexia. RESULTS: Cachexia was accompanied by preferential loss of adipose tissue and decreased fat cell volume, but not number. Adipose tissue pathways regulating energy turnover were upregulated, whereas genes in pathways related to cell and tissue structure (cellular adhesion, extracellular matrix and actin cytoskeleton) were downregulated in cachectic patients. Transcriptional response elements for hepatic nuclear factor-4 (HNF4) were overrepresented in the promoters of extracellular matrix and adhesion molecule genes, and adipose HNF4 mRNA was downregulated in cachexia. CONCLUSIONS: Cancer cachexia is characterised by preferential loss of adipose tissue; muscle mass is less affected. Loss of adipose tissue is secondary to a decrease in adipocyte lipid content and associates with changes in the expression of genes that regulate energy turnover, cytoskeleton and extracellular matrix, which suggest high tissue remodelling. Changes in gene expression in cachexia are reciprocal to those observed in obesity, suggesting that regulation of fat mass at least partly corresponds to two sides of the same coin.</p>
  •  
43.
  • Dalen, Helge, et al. (författare)
  • a-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-?B activation
  • 2003
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 88:1, s. 153-158
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Activation of nuclear factor-?B (NF-?B) can interfere with induction of apoptosis triggered by the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL, Apo2L). Therefore, agents that suppress NF-?B activation may sensitise cells to TRAIL-dependent apoptosis. Exposure of Jurkat cells to TRAIL resulted in massive and saturable apoptosis induction, following an initial lag time. This lag was abolished by pretreatment of the cells with subapoptotic doses of a-tocopheryl succinate (a-TOS) or the proteasome inhibitor MGI32. Exposure of the cells to TRAIL led to a rapid, transient activation of NF-?B, a process that was suppressed by cell pretreatment with a-TOS or MGI32. Activation of NF-?B by TNF-a prior to TRAIL exposure increased resistance of the cells to TRAIL-mediated apoptosis. We conclude that a-TOS sensitises cells to TRAIL killing, at least in some cases, through inhibition of NF-?B activation. This further supports the possibility that this semisynthetic analogue of vitamin E is a potential adjuvant in cancer treatment, such as in the case of TRAIL-mediated inhibition of cancer.</p>
  •  
44.
  •  
45.
  • Discacciati, A., et al. (författare)
  • Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer : a population-based prospective study
  • 2011
  • Ingår i: British Journal of Cancer. - Nature Publishing Group. - 0007-0920 .- 1532-1827. ; 105:7, s. 1061-1068
  • Tidskriftsartikel (refereegranskat)abstract
    • <p><strong>BACKGROUND</strong>: The relationships between body mass index (BMI) during early and middle-late adulthood and incidence of prostate cancer (PCa) by subtype of the disease (localised, advanced) and fatal PCa is unclear.</p><p><strong>METHODS</strong>: A population-based cohort of 36,959 Swedish men aged 45-79 years was followed up from January 1998 through December 2008 for incidence of PCa (1530 localised and 554 advanced cases were diagnosed) and through December 2007 for PCa mortality (225 fatal cases).</p><p><strong>RESULTS</strong>: From a competing-risks analysis, incidence of localised PCa was observed to be inversely associated with BMI at baseline (middle-late adulthood; rate ratio (RR) for 35 kg m(-2) when compared with 22 kg m(-2) was 0.69 (95% CI 0.52-0.92)), but not at age 30. For fatal PCa, BMI at baseline was associated with a nonstatistically significant increased risk (RR for every five-unit increase: 1.12 (0.88-1.43)) and BMI at age 30 with a decreased risk (RR for every five-unit increase: 0.72 (0.51-1.01)).</p><p><strong>CONCLUSION</strong>: Our results indicate an inverse association between obesity during middle-late, but not early adulthood, and localised PCa. They also suggest a dual association between BMI and fatal PCa--a decreased risk among men who were obese during early adulthood and an increased risk among those who were obese during middle-late adulthood.</p>
  •  
46.
  • Disney-Hogg, Linden, et al. (författare)
  • Influence of obesity-related risk factors in the aetiology of glioma
  • 2018
  • Ingår i: British Journal of Cancer. - Nature Publishing Group. - 0007-0920 .- 1532-1827. ; 118:7, s. 1020-1027
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>BACKGROUND: Obesity and related factors have been implicated as possible aetiological factors for the development of glioma in epidemiological observation studies. We used genetic markers in a Mendelian randomisation framework to examine whether obesity-related traits influence glioma risk. This methodology reduces bias from confounding and is not affected by reverse causation. METHODS: Genetic instruments were identified for 10 key obesity-related risk factors, and their association with glioma risk was evaluated using data from a genome-wide association study of 12,488 glioma patients and 18,169 controls. The estimated odds ratio of glioma associated with each of the genetically defined obesity-related traits was used to infer evidence for a causal relationship. RESULTS: No convincing association with glioma risk was seen for genetic instruments for body mass index, waist-to-hip ratio, lipids, type-2 diabetes, hyperglycaemia or insulin resistance. Similarly, we found no evidence to support a relationship between obesity-related traits with subtypes of glioma-glioblastoma (GBM) or non-GBM tumours. CONCLUSIONS: This study provides no evidence to implicate obesity-related factors as causes of glioma.</p>
  •  
47.
  •  
48.
  • Dyrskjot, L., et al. (författare)
  • Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR
  • 2012
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 107:8, s. 1392-1398
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>BACKGROUND: Multiple clinical risk factors and genetic profiles have been demonstrated to predict progression of non-muscle invasive bladder cancer; however, no easily clinical applicable gene signature has been developed to predict disease progression independent of disease stage and grade. METHODS: We measured the intra-patient variation of an 88-gene progression signature using 39 metachronous tumours from 17 patients. For delineation of the optimal quantitative reverse transcriptase PCR panel of markers, we used 115 tumour samples from patients in Denmark, Sweden, UK and Spain. RESULTS: Analysis of intra-patient variation of the molecular markers showed 71% similar classification results. A final panel of 12 genes was selected, showing significant correlation with outcome. In multivariate Cox regression analysis, we found that the 12-gene signature was an independent prognostic factor (hazard ratio = 7.4 (95% confidence interval: 3.4-15.9), P &lt; 0.001) when adjusting for stage, grade and treatment. Independent validation of the 12-gene panel and the determined cut-off values is needed and ongoing. CONCLUSION: Intra-patient marker variation in metachronous tumours is present. Therefore, to increase test sensitivity, it may be necessary to test several metachronous tumours from a patient's disease course. A PCR-based 12-gene signature significantly predicts disease progression in patients with non-muscle invasive bladder cancer.</p>
  •  
49.
  • Eberhard, J., et al. (författare)
  • A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer
  • 2012
  • Ingår i: British Journal of Cancer. - 0007-0920 .- 1532-1827. ; 106:5, s. 931-938
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. In this study, we validated the prognostic ability of SATB2 expression in a large, prospective CRC cohort. METHODS: Immunohistochemical SATB2 expression was assessed in 527 incident CRC cases from the Malmo Diet and Cancer Study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on cancer-specific survival (CSS) and overall survival (OS). RESULTS: High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR)=0.61; 95% CI 0.41-0.92) and in colon cancer (HR=0.39; 95% CI 0.20-0.75), remaining significant in multivariable analysis of colon cancer (HR 0.49; 95% CI 0.25-0.96), with similar findings for OS. In curatively resected stage III-IV patients, a significant benefit from adjuvant and/or neoadjuvant therapy was observed for SATB2 high tumours (P-interaction 0.037 for OS) and high SATB2 expression in rectal cancer correlated with an enhanced effect of neoadjuvant therapy (P-interaction 0.033 for OS). CONCLUSION: High SATB2 expression is an independent marker of good prognosis in colon cancer and may modulate sensitivity to chemotherapy and radiation. British Journal of Cancer (2012) 106, 931-938. doi:10.1038/bjc.2012.34 www.bjcancer.com Published online 14 February 2012</p>
  •  
50.
  • Eklöf, Vincy, 1984-, et al. (författare)
  • The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
  • 2013
  • Ingår i: British Journal of Cancer. - Nature Publishing Group. - 0007-0920 .- 1532-1827. ; 108:10, s. 2153-2163
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Background Mutations in KRAS, BRAF, PIK3CA and PTEN expression have been in focus to predict the effect of epidermal growth factor receptor-blocking therapy in colorectal cancer (CRC). Here, information on these four aberrations was collected and combined to a Quadruple index and used to evaluate the prognostic role of these factors in CRC. Patients We analysed the mutation status in KRAS, BRAF and PIK3CA and PTEN expression in two separate CRC cohorts, Northern Sweden Health Disease Study (NSHDS; n = 197) and Colorectal Cancer in Umea Study (CRUMS; n = 414). A Quadruple index was created, where Quadruple index positivity specifies cases with any aberration in KRAS, BRAF, PIK3CA or PTEN expression. Results Quadruple index positive tumours had a worse prognosis, significant in the NSHDS but not in the CRUMS cohort (NSHDS; P = 0.003 and CRUMS; P = 0.230) in univariate analyses but significance was lost in multivariate analyses. When analysing each gene separately, only BRAF was of prognostic significance in the NSHDS cohort (multivariate HR 2.00, 95% CI: 1.16-3.43) and KRAS was of prognostic significance in the CRUMS cohort (multivariate HR 1.48, 95% CI: 1.02-2.16). Aberrations in PIK3CA and PTEN did not add significant prognostic information. Conclusions Our results suggest that establishment of molecular subgroups based on KRAS and BRAF mutation status is important and should be considered in future prognostic studies in CRC.</p>
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (63)
Typ av publikation
tidskriftsartikel (813)
forskningsöversikt (4)
konferensbidrag (2)
Typ av innehåll
refereegranskat (804)
övrigt vetenskapligt (21)
Författare/redaktör
Wolk, A, (37)
Trichopoulou, A (36)
Weiderpass, E, (32)
Overvad, K (32)
Kaaks, R (30)
Tumino, R (29)
visa fler...
Riboli, E (28)
Trichopoulos, D (28)
Tjonneland, A (26)
Boeing, H (26)
Adami, HO, (26)
Khaw, K. T. (25)
Palli, D (24)
Dillner, J, (23)
Glimelius, B, (23)
Auer, G, (23)
Olsson, Håkan, (21)
Bueno-de-Mesquita, H ... (20)
Ekbom, A (19)
Andersson, S (19)
Ardanaz, E (18)
Clavel-Chapelon, F (18)
Glimelius, Bengt, (17)
Ye, W. (17)
Hall, P, (17)
Lagiou, P (17)
Steineck, G, (17)
Peterlongo, P (16)
Panico, S (16)
Hemminki, K (16)
Lagergren, J, (16)
Benitez, J. (15)
Lindblom, A, (14)
Chenevix-Trench, G (14)
Ferrari, P. (13)
Key, T. J. (13)
Kogner, P, (13)
Nyren, O, (13)
Vineis, P (13)
Jenab, M (13)
Larranaga, N (13)
Nevanlinna, H (12)
Olsen, A (12)
Holmberg, Lars, (12)
Boffetta, P (12)
Czene, K, (12)
Bergstrom, R (12)
Norat, T (12)
Ahlman, Håkan, 1947- ... (12)
Beesley, J (12)
visa färre...
Lärosäte
Karolinska Institutet (418)
Lunds universitet (155)
Uppsala universitet (112)
Umeå universitet (70)
Göteborgs universitet (56)
Linköpings universitet (46)
visa fler...
Örebro universitet (15)
Chalmers tekniska högskola (5)
Kungliga Tekniska Högskolan (4)
Mälardalens högskola (4)
swepub_uni:mau_t (4)
Stockholms universitet (2)
Högskolan i Jönköping (2)
Södertörns högskola (1)
Mittuniversitetet (1)
Karlstads universitet (1)
visa färre...
Språk
Engelska (813)
Odefinierat språk (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (416)
Naturvetenskap (11)
Samhällsvetenskap (3)
Teknik (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy